Tina Baykaner, MD
Cardiovascular Disease (Cardiology) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Offices
- 4
Offices
4 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Baykaner’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A120124 · Current
Licensed to practise in California · since 2012 · expires 2027-06-30 · Hacettepe University Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$127,796
Medicare paid this office $127,796 for 753 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 35 | $28,287 | $786 |
| Long return visit (40+ min) | 57 | $9,574 | $147 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 107 | $7,163 | $26 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 16 | $7,131 | $446 |
| New patient visit (60+ min) | 34 | $6,641 | $195 |
See all 19 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 35 | $28,287 | $786 |
| Long return visit (40+ min) | 57 | $9,574 | $147 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 107 | $7,163 | $26 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 16 | $7,131 | $446 |
| New patient visit (60+ min) | 34 | $6,641 | $195 |
| Long return visit (40+ min) | 54 | $6,598 | $114 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $6,515 | $152 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 16 | $5,336 | $254 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 59 | $4,619 | $31 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $3,127 | $104 |
| New patient visit (60+ min) | 19 | $2,982 | $157 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 341 | $2,650 | $7 |
| Programming of dual lead pacemaker system | 51 | $2,357 | $33 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 76 | $1,780 | $23 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,048 | $87 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 16 | $1,002 | $22 |
| Programming of multiple lead implantable defibrillator system | 14 | $868 | $54 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 18 | $189 | $10 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 12 | $169 | $14 |
Procedures Medicare counted
| Pacemaker insertion or repair | 22 | More than 73% of doctors who do this |
Who their Medicare patients are
753 Original Medicare patients in 2024. Average age 75 · Under 65 10% · 85 and older 18% · Women 47% · Also on Medicaid 26% · Health risk score 2.02. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Atrial fibrillation 57% · Coronary heart disease 46% · Heart failure 42% · Chronic kidney disease 42% · Diabetes 34% · Cancer 23% · Depression 22% · COPD 16% · Stroke 16% · Dementia 13%.
The office billed $1,019,661, Medicare allowed $165,988 and paid $127,796; for 1,526 services of 59 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 753 | 1,526 | 75 | 2.02 | $1,019,661 | $127,796 |
| 2023 | 1,043 | 1,871 | 75 | 2.02 | $841,405 | $118,158 |
| 2022 | 543 | 1,008 | 76 | 2.09 | $617,650 | $83,884 |
| 2021 | 371 | 883 | 75 | 2.00 | $681,778 | $105,216 |
| 2020 | 358 | 825 | 75 | 2.16 | $579,012 | $88,346 |
| 2019 | 319 | 678 | 73 | 2.34 | $394,158 | $77,871 |
| 2018 | 73 | 134 | 73 | 2.26 | $124,385 | $24,329 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 19 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 22 | $18,020 | $819 |
| Long return visit (40+ min) | 99 | $14,520 | $124 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 56 | $10,555 | $160 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $6,495 | $108 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 14 | $6,491 | $464 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 610 | $6,138 | $7 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 83 | $4,823 | $27 |
| New patient visit (60+ min) | 26 | $3,885 | $149 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 55 | $3,608 | $33 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 13 | $3,483 | $268 |
| Hospital discharge day management, more than 30 minutes | 27 | $2,892 | $107 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 94 | $2,321 | $24 |
| Programming of dual lead pacemaker system | 48 | $2,152 | $32 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,315 | $120 |
| Programming of multiple lead implantable defibrillator system | 17 | $1,309 | $57 |
| Programming of dual lead implantable defibrillator system | 18 | $891 | $47 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 13 | $625 | $24 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 13 | $189 | $15 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 12 | $62 | $5 |
2022: 12 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 19 | $18,498 | $974 |
| Long return visit (40+ min) | 92 | $12,527 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $4,983 | $94 |
| New patient visit (60+ min) | 29 | $4,535 | $156 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 61 | $3,146 | $27 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $3,087 | $182 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 48 | $2,870 | $31 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 97 | $2,709 | $24 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 203 | $1,690 | $7 |
| Hospital discharge day management, more than 30 minutes | 16 | $1,577 | $99 |
| Programming of dual lead pacemaker system | 35 | $1,412 | $34 |
| Programming of dual lead implantable defibrillator system | 11 | $686 | $49 |
2021: 17 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 20 | $19,992 | $1,000 |
| Insertion of implantable defibrillator system | 12 | $10,091 | $841 |
| Long return visit (40+ min) | 69 | $9,972 | $128 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 23 | $6,071 | $264 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,071 | $185 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 75 | $3,824 | $27 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 50 | $3,426 | $34 |
| Return visit (30+ min) | 32 | $2,966 | $90 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 24 | $2,777 | $116 |
| New patient visit (60+ min) | 13 | $2,241 | $172 |
| Programming of multiple lead implantable defibrillator system | 15 | $1,711 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,623 | $95 |
| Programming of dual lead pacemaker system | 35 | $1,583 | $35 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 44 | $1,162 | $23 |
| Short return visit (20+ min) | 11 | $691 | $63 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 12 | $668 | $25 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 63 | $509 | $8 |
2020: 20 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 14 | $14,019 | $1,001 |
| Insertion of implantable defibrillator system | 16 | $13,526 | $845 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 15 | $7,107 | $474 |
| Long return visit (40+ min) | 55 | $6,016 | $97 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 15 | $3,970 | $265 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 85 | $3,866 | $26 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 45 | $2,699 | $31 |
| Return visit (30+ min) | 37 | $2,655 | $68 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,275 | $190 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 13 | $1,759 | $135 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,629 | $96 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,389 | $126 |
| Short return visit (20+ min) | 26 | $1,272 | $42 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 47 | $1,234 | $23 |
| Programming of dual lead pacemaker system | 29 | $1,104 | $32 |
| Programming of dual lead implantable defibrillator system | 13 | $817 | $54 |
| Programming of multiple lead implantable defibrillator system | 14 | $791 | $47 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 66 | $543 | $8 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 11 | $526 | $22 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 20 | $224 | $11 |
2019: 18 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 11 | $10,715 | $974 |
| Long return visit (40+ min) | 95 | $10,606 | $95 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 12 | $5,505 | $459 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,522 | $181 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 12 | $3,342 | $257 |
| New patient visit (60+ min) | 21 | $3,152 | $150 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 14 | $1,973 | $132 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $1,952 | $93 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,951 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,431 | $65 |
| Programming of dual lead pacemaker system | 30 | $1,392 | $35 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 20 | $1,297 | $41 |
| Programming of multiple lead implantable defibrillator system | 16 | $1,266 | $55 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,075 | $98 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 105 | $920 | $8 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 19 | $718 | $27 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 12 | $442 | $34 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 18 | $435 | $24 |
2018: 2 services
| New patient visit (60+ min) | 14 | $2,107 | $151 |
| Long return visit (40+ min) | 20 | $1,995 | $100 |
Medicaid work
$3,229 in 2024
Medicaid paid $3,229 for 297 billed services this clinician did in 2024, up to 92 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 246 | $2,383 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead implantable defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 14 | $368 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, or leadless pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 25 | $306 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 12 | $173 |
| 2024 | 297 | 4 | 92 | $3,229 |
| 2023 | 701 | 3 | 325 | $8,563 |
| 2022 | 210 | 3 | 75 | $3,942 |
| 2021 | 75 | 2 | 60 | $1,058 |
| 2020 | 73 | 1 | 42 | $854 |
| 2019 | 83 | 1 | 73 | $765 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 639 | $5,478 |
| Long return visit (40+ min) | 46 | $2,927 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 16 | $159 |
2022
| Long return visit (40+ min) | 26 | $2,143 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 172 | $1,556 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 12 | $243 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 62 | $662 |
| Long return visit (40+ min) | 13 | $395 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 73 | $854 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 83 | $765 |
Drugs they prescribed that Part D paid
$190,060
Pharmacies billed $190,060 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 504) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
358 generic and 146 brand-name prescriptions · $190,060 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 108 | $137,323 | $1,272 |
| Xarelto | 20 | $26,836 | $1,342 |
| Flecainide Acetate | 76 | $3,177 | $42 |
| Mexiletine | 14 | $1,851 | $132 |
| Metoprolol | 89 | $1,246 | $14 |
See all 10 drugs
| Eliquis | 108 | $137,323 | $1,272 |
| Xarelto | 20 | $26,836 | $1,342 |
| Flecainide Acetate | 76 | $3,177 | $42 |
| Mexiletine | 14 | $1,851 | $132 |
| Metoprolol | 89 | $1,246 | $14 |
| Amiodarone | 33 | $714 | $22 |
| Sucralfate | 26 | $417 | $16 |
| Carvedilol | 16 | $192 | $12 |
| Pantoprazole | 22 | $174 | $8 |
| Metoprolol | 12 | $86 | $7 |
Year by year
| 2024 | 504 | 122 | 0% (0) | 29% | $190,060 |
| 2023 | 433 | 102 | 0% (0) | 28% | $185,411 |
| 2022 | 395 | 97 | 0% (0) | None | $202,552 |
| 2021 | 406 | 97 | 0% (0) | 36% | $193,280 |
| 2020 | 376 | 73 | 0% (0) | 29% | $127,055 |
| 2019 | 205 | 53 | None | 34% | $54,235 |
| 2018 | 23 | 11 | 0% (0) | None | $2,559 |
| 2016 | 23 | None | 0% (0) | None | $724 |
| 2015 | 99 | 28 | 0% (0) | 24% | $6,724 |
| 2014 | 314 | 52 | None | 23% | $16,039 |
| 2013 | 343 | 82 | None | None | $25,202 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Eliquis | 96 | $135,853 | $1,415 |
| Xarelto | 15 | $23,871 | $1,591 |
| Amiodarone | 23 | $4,430 | $193 |
| Dofetilide | 16 | $4,142 | $259 |
| Flecainide Acetate | 82 | $4,069 | $50 |
| Metoprolol | 58 | $1,274 | $22 |
| Sotalol | 17 | $427 | $25 |
| Sucralfate | 23 | $382 | $17 |
| Pantoprazole | 15 | $120 | $8 |
| Metoprolol | 11 | $119 | $11 |
2022: 10 drugs
| Eliquis | 101 | $125,855 | $1,246 |
| Xarelto | 17 | $26,217 | $1,542 |
| Flecainide Acetate | 59 | $4,869 | $83 |
| Dofetilide | 14 | $3,927 | $281 |
| Amiodarone | 20 | $1,009 | $50 |
| Sucralfate | 20 | $935 | $47 |
| Metoprolol | 39 | $724 | $19 |
| Sotalol | 18 | $400 | $22 |
| Pantoprazole | 23 | $195 | $8 |
| Spironolactone | 12 | $119 | $10 |
2021: 10 drugs
| Eliquis | 90 | $97,026 | $1,078 |
| Xarelto | 27 | $36,343 | $1,346 |
| Multaq | 16 | $29,685 | $1,855 |
| Amiodarone | 15 | $2,684 | $179 |
| Flecainide Acetate | 33 | $2,342 | $71 |
| Metoprolol | 63 | $1,280 | $20 |
| Sucralfate | 19 | $913 | $48 |
| Sotalol | 15 | $618 | $41 |
| Pantoprazole | 23 | $264 | $11 |
| Losartan | 11 | $129 | $12 |
2020: 9 drugs
| Eliquis | 65 | $62,603 | $963 |
| Xarelto | 25 | $29,920 | $1,197 |
| Metoprolol | 68 | $2,214 | $33 |
| Flecainide Acetate | 36 | $1,852 | $51 |
| Amiodarone | 21 | $1,561 | $74 |
| Losartan | 12 | $194 | $16 |
| Spironolactone | 14 | $137 | $10 |
| Carvedilol | 11 | $108 | $10 |
| Amlodipine Besylate | 13 | $60 | $5 |
2019: 6 drugs
| Eliquis | 34 | $22,513 | $662 |
| Multaq | 15 | $9,812 | $654 |
| Xarelto | 12 | $8,473 | $706 |
| Metoprolol | 41 | $2,006 | $49 |
| Dofetilide | 11 | $1,441 | $131 |
| Pantoprazole | 12 | $101 | $8 |
2015: 1 drug
| Carvedilol | 12 | $45 | $4 |
2014: 9 drugs
| Pradaxa | 11 | $3,303 | $300 |
| Clopidogrel | 18 | $1,036 | $58 |
| Atorvastatin | 30 | $547 | $18 |
| Isosorbide Mononitrate Er | 15 | $400 | $27 |
| Spironolactone | 23 | $180 | $8 |
| Metoprolol | 20 | $176 | $9 |
| Furosemide | 33 | $144 | $4 |
| Lisinopril | 16 | $125 | $8 |
| Amlodipine Besylate | 19 | $108 | $6 |
2013: 8 drugs
| Carvedilol | 45 | $1,023 | $23 |
| Metoprolol | 13 | $1,014 | $78 |
| Atorvastatin | 15 | $860 | $57 |
| Bumetanide | 21 | $545 | $26 |
| Potassium Chloride | 16 | $448 | $28 |
| Lisinopril | 27 | $341 | $13 |
| Furosemide | 36 | $233 | $6 |
| Amlodipine Besylate | 12 | $97 | $8 |
Money from drug and device companies
$49,926 in 2025
| 2025 | 7 | 92 | $36,450 | $49,926 |
| 2024 | 9 | 63 | $16,600 | $42,945 |
| 2023 | 6 | 38 | $4,863 | $11,675 |
| 2022 | 3 | 83 | $10,051 | $42,503 |
| 2021 | 2 | 30 | $5,188 | $8,369 |
| 2020 | 2 | 20 | $6,625 | $9,533 |
| 2019 | 4 | 30 | None | $2,794 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Farapulse | $25,352 | 25 payments
|
| Medtronic | Affera Mapping System | $15,108 | 38 payments
|
| Abbott Laboratories | Tacticath Ablation Catheter, Sensor Enabled | $3,023 | 12 payments
|
| Volta Medical | Vx1 | $2,200 | 1 payment
|
| Biosense Webster | Carto 3 | $2,116 | 14 payments
|
| Biotronik | None | $2,000 | 1 payment
|
See all 92 published payments
| Abbott Laboratories | Travel · 2025-12-24 | Tacticath Ablation Catheter, Sensor Enabled | $139 |
| Medtronic | Paid to speak or teach · 2025-12-18 | None | $6,300 |
| Biosense Webster | Travel · 2025-12-15 | Carto 3 | $161 |
| Biosense Webster | Meals · 2025-12-11 | Carto 3 | $19 |
| Biosense Webster | Travel · 2025-12-11 | Carto 3 | $523 |
| Biosense Webster | Meals · 2025-12-11 | Carto 3 | $21 |
| Biosense Webster | Meals · 2025-12-11 | Carto 3 | $18 |
| Biosense Webster | Meals · 2025-12-11 | Carto 3 | $24 |
| Biosense Webster | Meals · 2025-12-11 | Carto 3 | $33 |
| Biosense Webster | Meals · 2025-12-11 | Carto 3 | $67 |
| Biosense Webster | Meals · 2025-12-11 | Carto 3 | $55 |
| Biosense Webster | Meals · 2025-12-11 | Carto 3 | $25 |
| Biosense Webster | Meals · 2025-12-11 | Carto 3 | $60 |
| Biosense Webster | Meals · 2025-12-11 | Carto 3 | $128 |
| Medtronic | Travel · 2025-12-11 | None | $504 |
| Medtronic | Meals · 2025-12-10 | None | $159 |
| Medtronic | Meals · 2025-12-07 | None | $75 |
| Medtronic | Meals · 2025-12-07 | None | $52 |
| Medtronic | Meals · 2025-12-07 | None | $35 |
| Medtronic | Meals · 2025-12-06 | Affera Mapping System | $10 |
| Medtronic | Travel · 2025-12-06 | None | $269 |
| Medtronic | Travel · 2025-12-06 | None | $38 |
| Medtronic | Meals · 2025-12-06 | None | $84 |
| Medtronic | Meals · 2025-12-06 | None | $106 |
| Medtronic | Meals · 2025-12-06 | None | $75 |
| Medtronic | Meals · 2025-12-06 | None | $21 |
| Medtronic | Meals · 2025-12-05 | Affera Mapping System | $110 |
| Medtronic | Travel · 2025-12-05 | None | $269 |
| Medtronic | Travel · 2025-12-05 | None | $37 |
| Medtronic | Meals · 2025-12-05 | None | $187 |
| Boston Scientific | Paid to speak or teach · 2025-11-06 | Farapulse | $7,500 |
| Boston Scientific | Paid to speak or teach · 2025-11-06 | Farapulse | $625 |
| Medtronic | Meals · 2025-11-04 | Affera Mapping System | $29 |
| Merit Medical Systems | Meals · 2025-10-29 | Heartspan Steerable Sheath Introducer | $126 |
| Boston Scientific | Meals · 2025-10-26 | Watchman | $61 |
| Abbott Laboratories | Meals · 2025-10-22 | Ensite | $48 |
| Biosense Webster | Travel · 2025-10-07 | Carto 3 | $532 |
| Boston Scientific | Meals · 2025-10-04 | Farapulse | $20 |
| Boston Scientific | Meals · 2025-10-04 | Farapulse | $60 |
| Boston Scientific | Meals · 2025-10-04 | Farapulse | $455 |
| Boston Scientific | Travel · 2025-10-04 | Farapulse | $377 |
| Boston Scientific | Meals · 2025-10-03 | Farapulse | $550 |
| Boston Scientific | Travel · 2025-10-03 | Farapulse | $377 |
| Boston Scientific | Travel · 2025-10-03 | Farapulse | $372 |
| Boston Scientific | Meals · 2025-10-02 | Watchman Flx | $145 |
| Boston Scientific | Meals · 2025-10-02 | Farapulse | $10 |
| Boston Scientific | Travel · 2025-10-02 | Farapulse | $377 |
| Boston Scientific | Travel · 2025-10-02 | Farapulse | $457 |
| Medtronic | Meals · 2025-08-06 | Affera Mapping System | $7 |
| Medtronic | Meals · 2025-07-21 | Affera Mapping System | $167 |
| Boston Scientific | Paid to speak or teach · 2025-07-16 | General - Therapies | $5,000 |
| Boston Scientific | Paid to speak or teach · 2025-07-16 | General - Therapies | $625 |
| Abbott Laboratories | Meals · 2025-07-09 | Ensite Precision | $19 |
| Boston Scientific | Paid to speak or teach · 2025-07-03 | Farapulse | $5,000 |
| Abbott Laboratories | Meals · 2025-06-24 | Ensite | $32 |
| Abbott Laboratories | Meals · 2025-06-16 | Ensite Precision | $96 |
| Boston Scientific | Meals · 2025-06-07 | General - Therapies | $453 |
| Boston Scientific | Travel · 2025-06-07 | General - Therapies | $381 |
| Boston Scientific | Meals · 2025-06-06 | General - Therapies | $682 |
| Boston Scientific | Travel · 2025-06-06 | General - Therapies | $381 |
| Boston Scientific | Travel · 2025-06-05 | General - Therapies | $760 |
| Boston Scientific | Travel · 2025-06-05 | General - Therapies | $381 |
| Boston Scientific | Travel · 2025-06-05 | General - Therapies | $218 |
| Medtronic | Meals · 2025-05-31 | Cobalt Dr Mri Surescan | $30 |
| Abbott Laboratories | Meals · 2025-05-30 | Ensite Precision | $120 |
| Abbott Laboratories | Travel · 2025-05-30 | Tacticath Ablation Catheter, Sensor Enabled | $39 |
| Abbott Laboratories | Meals · 2025-05-22 | Ensite Precision | $156 |
| Abbott Laboratories | Meals · 2025-05-22 | Tacticath Ablation Catheter, Sensor Enabled | $28 |
| Volta Medical | Consulting · 2025-05-19 | Vx1 | $2,200 |
| Abbott Laboratories | Consulting · 2025-05-15 | Tacticath Ablation Catheter, Sensor Enabled | $2,100 |
| Abbott Laboratories | Travel · 2025-05-06 | Tacticath Ablation Catheter, Sensor Enabled | $239 |
| Abbott Laboratories | Travel · 2025-05-06 | Tacticath Ablation Catheter, Sensor Enabled | $9 |
| Medtronic | Meals · 2025-05-03 | Aurora Ev-Icd Mri Surescan | $38 |
| Medtronic | Meals · 2025-04-24 | Affera Mapping System | $40 |
| Boston Scientific | Meals · 2025-04-23 | General - Therapies | $82 |
| Biosense Webster | Consulting · 2025-02-19 | None | $450 |
| Medtronic | Paid to speak or teach · 2025-01-22 | None | $4,650 |
| Medtronic | Meals · 2025-01-17 | Affera Mapping System | $42 |
| Medtronic | Meals · 2025-01-17 | Linq II | $112 |
| Medtronic | Travel · 2025-01-15 | None | $101 |
| Medtronic | Travel · 2025-01-15 | None | $135 |
| Medtronic | Meals · 2025-01-14 | Affera Mapping System | $60 |
| Medtronic | Travel · 2025-01-14 | None | $101 |
| Medtronic | Travel · 2025-01-14 | None | $171 |
| Medtronic | Travel · 2025-01-14 | None | $26 |
| Medtronic | Travel · 2025-01-13 | None | $171 |
| Medtronic | Travel · 2025-01-13 | None | $26 |
| Medtronic | Meals · 2025-01-09 | None | $46 |
| Medtronic | Meals · 2025-01-09 | None | $28 |
| Biotronik | Consulting · 2025-01-07 | None | $2,000 |
| Medtronic | Travel · 2025-01-03 | None | $762 |
| Medtronic | Travel · 2025-01-03 | None | $35 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $42,945
| Volta Medical | Vx1 | $14,355 | 5 payments
|
| Medical Device Business Services | Carto 3 | $13,026 | 2 payments
|
| Medtronic | Linq II | $11,916 | 36 payments
|
| Biotronik | None | $2,343 | 11 payments
|
| iRhythm Technologies | Zio Xt Patch | $875 | 1 payment
|
| Abbott Laboratories | Ensite Precision | $178 | 5 payments
|
| Biosense Webster | Carto 3 | $103 | 1 payment
|
| Boston Scientific | None | $91 | 1 payment
|
| Philips North America | (9274) Lld | $58 | 1 payment
|
2023: $11,675
| Medtronic | Cobalt Dr Mri Surescan | $5,670 | 16 payments
|
| Philips North America | (9520) Igt Devices Undivided | $2,088 | 2 payments
|
| AltaThera Pharmaceuticals | Sotalol Hydrochloride | $1,800 | 1 payment
|
| Biotronik | None | $1,475 | 14 payments
|
| Philips Electronics North America | (9520) Igt Devices Undivided | $522 | 4 payments
|
| Abbott Laboratories | Tacticath Ablation Catheter, Sensor Enabled | $119 | 1 payment
|
2022: $42,503
| Biotronik | Edora 8 Dr-T | $26,894 | 53 payments
|
| Abbott Laboratories | Ensite Precision | $10,428 | 11 payments
|
| Medtronic | Micra | $5,181 | 19 payments
|
2021: $8,369
| Biotronik | Edora | $4,524 | 19 payments
|
| Medtronic | Arctic Front | $3,845 | 11 payments
|
2020: $9,533
| Biotronik | None | $7,908 | 18 payments
|
| Medtronic Vascular | None | $1,625 | 2 payments
|
2019: $2,794
| Medtronic Vascular | Arctic Front | $2,371 | 26 payments
|
| Biosense Webster | Carto 3 System | $154 | 2 payments
|
| Boston Scientific | General Therapies | $149 | 1 payment
|
| Abbott Laboratories | Fortify Assura, Ellipse Icd | $119 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Janssen Research & Development, LLC · A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study To Evaluate the Efficacy and Safety of Milvexian, An Oral Factor Xia Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation · 2025 | Their institution | $270,024 |
| Janssen Research & Development, LLC · 2024 | Their institution | $35,729 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1760786818
- Licence
- CA A120124California A120124: Current · expires 2027-06-30
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0001X (207RC0001X); Internal medicine (207R00000X); Cardiology (207RC0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2011-01-04
- NPI last updated
- 2024-04-17
- NPI record certified
- 2024-04-17
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 8939 Villa La Jolla Dr Ste 111, La Jolla, CA, 92037 · 300 Pasteur Dr, Stanford, CA, 94305 · 300 Pasteur Drive, Stanford, CA, 94305